Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$7.03
+0.10 (+1.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $439.0M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.9B
P/E
15.0x
↓EV/EBITDA
6.2x
↓ROE
9.5%
↑Gross Margin
61.2%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.4%
FCF CAGR
+15.7%
FCF margin
52.1%
FCF / Net income
1.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.51B · net income $397.2M · FCF $788.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.51B | $1.51B | $1.61B | $1.52B | $1.73B |
| Net Income | $397.2M | $397.2M | $500.3M | $540.4M | $645.9M |
| EBITDA | $608.7M | $608.7M | $724.4M | $776.3M | $906.1M |
| EPS | 0.47 | 0.47 | 0.60 | 0.65 | 0.77 |
| Gross Margin | 61.2% | 61.2% | 66.1% | 68.7% | 66.4% |
| Operating Margin | 35.4% | 35.4% | 35.6% | 41.9% | 47.1% |
| Net Margin | 26.2% | 26.2% | 31.0% | 35.4% | 37.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Current Ratio | 19.65 | 19.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $788.3M | $788.3M | $-260.4M | $439.0M | $508.9M |
| Returns | |||||
| ROE | 9.5% | 9.5% | 12.3% | 14.0% | 17.9% |
| Valuation | |||||
| P/E | 14.96 | 14.96 | 14.00 | 18.62 | 14.94 |
| EV/EBITDA | 6.22 | 6.22 | 7.43 | 11.93 | 8.54 |
| P/B | 1.41 | 1.41 | 1.73 | 2.62 | 2.67 |
| Growth & Yield | |||||
| Revenue Growth | -6.1% | -6.1% | 5.7% | -11.9% | — |
| EPS Growth | -21.7% | -21.7% | -7.7% | -15.6% | — |
| Dividend Yield | 5.3% | 5.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
9.9%
EPS terminal req.
$0.62
Spread vs growth
-31.6%
5Y implied EPS CAGR
9.9%
EPS terminal req.
$0.75
Spread vs growth
-31.6%
10Y implied EPS CAGR
10.0%
EPS terminal req.
$1.22
Spread vs growth
-31.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.6%
Start / end P/E
14.6x → 15.0x
EPS bridge
0.60 → 0.47
Residual
-0.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.